


AMENDED CLAIMS

1-10. (Canceled)

11. (Currently amended) A parenteral pharmaceutical composition with injection site toleration comprising a therapeutically effective amount of a compound of Formula (la),



or a pharmaceutically acceptable salt thereof, a β -cyclodextrin, a pharmaceutically acceptable preservative, a pharmaceutically acceptable vehicle, and an optional pharmaceutically acceptable excipient, wherein the preservative demonstrates pharmaceutically acceptable antimicrobial preservative effectiveness and is selected from the group consisting of thimerosal, propylene glycol, phenol, or meta-cresol.

12. (Canceled)

13. (Previously presented) The pharmaceutical composition according to Claim 11 wherein the β -cyclodextrin is 2-hydroxypropyl- β -cyclodextrin or sulfobutyl ether- β -cyclodextrin.

14. (Canceled)

15. (Previously presented) The pharmaceutical composition according to claim 14 wherein the preservative is about 2.5 to about 3.5 mg/mL of meta-cresol, the cyclodextrin is sulfobutyl ether- β -cyclodextrin, and wherein the pharmaceutically acceptable salt is the citrate monohydrate salt.

16. (Previously presented) The pharmaceutical composition according to claim 14 wherein the preservative has a binding value to the cyclodextrin that is less than the binding value of the compound of Formula (1a) to cyclodextrin.

17-18. (Canceled)

19. (Previously presented) The pharmaceutical composition according to claim 16 wherein the binding value of the compound of Formula (1a) to cyclodextrin is between 800 M⁻¹ and 3,000 M⁻¹.

20-27. (Canceled)

28. (Previously presented) A pharmaceutical composition comprising about 10 mg/mL of a compound of Formula (1a), about 3.3 mg/mL meta-cresol, about 63 mg/mL sulfobutyl ether- β -cyclodextrin, and a pharmaceutically acceptable vehicle.

29. (Previously presented) A method for the treatment of emesis in an animal comprising administering to said animal a composition according to Claim 11.